Pharmaceuticals

credit of the month

davidson-jpg

Unattractive valuations and the overshadowing presence of patent pitfalls and litigation risk have combined to make the pharmaceutical sector one of the most interesting movers over the past few months.

Recently,Wyeth (WYE) was able to attract enough interest in a bond transaction to upsize the issue to $3 billion from $2.5 billion. Also, Schering-Plough (SPG) tapped the market for $2.4 billion in spite of ongoing legal issues and loss of patent protection on its Claritin product.

Just a month

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: